Meeting
2020 ASCO Virtual Scientific Program
Consolidation nivolumab/ipilimumab versus nivolumab following concurrent chemoradiation in patients with unresectable stage III NSCLC: A planned interim safety analysis from the BTCRC LUN 16-081 trial.
Authors
Melissa Yan
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, IN
Melissa Yan , Greg Andrew Durm , Hirva Mamdani , Vinicius Ernani , Salma K. Jabbour , Jarushka Naidoo , Borys Hrinczenko , Ticiana Leal , Lawrence Eric Feldman , Goetz H. Kloecker , Naomi Fujioka , Mary J. Fidler , Nasser H. Hanna
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT03285321
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9010)
DOI
10.1200/JCO.2020.38.15_suppl.9010
Abstract #
9010
Poster Bd #
203
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A phase II trial of consolidation nivolumab or nivolumab plus ipilimumab following concurrent chemoradiation in unresectable stage III NSCLC: BTCRC LUN16-081.
First Author: Greg Andrew Durm
Poster
2023 ASCO Annual Meeting
Phase 3 trial of durvalumab combined with domvanalimab following concurrent chemoradiotherapy (cCRT) in patients with unresectable stage III NSCLC (PACIFIC-8).
First Author: Mustafa Özgüroğlu
Poster
2022 ASCO Annual Meeting
Two-year update from KEYNOTE-799: Pembrolizumab plus concurrent chemoradiation therapy (cCRT) for unresectable, locally advanced, stage III NSCLC.
First Author: Martin Reck
Poster
2022 ASCO Annual Meeting
Consolidation nivolumab plus ipilimumab or nivolumab alone following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: BTCRC LUN 16-081.
First Author: Greg Andrew Durm